Médecine Nucléaire et Radiothérapie

Enhanced 2-deoxy-2- ( 18 F) fluoro-D-glucose (FDG) Uptake on PET-CT Due to a Benign Condition and Hodgkin ’ s Lymphoma

Abstract

Wendi G. O’Connor, Monte S. Willis and Arif Sheikh

The utility of FDG PET-CT in documenting malignant disease has been demonstrated for many disease processes. However, non-malignant causes for FDG PET-CT enhancement exist. Here we present an example of a 12 year-old male diagnosed with Hodgkin’s lymphoma that underwent an FDG PET-CT for evaluation and initial staging. The scan demonstrated disease in the chest and abdomen in addition to focal uptake in the left distal tibia that was considered to represent a focus of disease. Unexpectedly, as the disease was treated, the focal uptake in the leg did not decrease prompting additional CT and conventional radiograph imaging, which found that the lesion was consistent with Non-Ossifying Fibroma (NOF). This case illustrates that FDG PET-CT can identify both malignant disease and benign bone lesions that may masquerade as metastatic disease.